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Milestones in RNA vaccine
Mechanism of action of mRNA-based vaccines.2017
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mRNA Vaccine Era-Mechanisms  Drug Platform and clinical prospection(2020)
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Advantages of mRNA
• No potential risk of infection
• No risk of insertional mutagenesis
• Degraded by normal cellular process
• In vivo half-life can be regulated
safety
• Easily modifications 
• Efficient in-vivo delivery
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Kinds of mRNA vaccine 
• Encode the antigen of 
interest
• Viral replication machineryself-amplifying 
mRNA(SAM)
• Encode the antigen of 
interest
• Contain 5´& 3´UTRNon-replicatingmRNA(NMR)
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The promise of mRNA vaccines: a biotech and industrial perspective 2020
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Self-amplifying RNA( SAM)
Based on alpha virus genome
RNA replication machinery gens are intact
Structural protein gens are replaced with the antigen of 
interest
Length is 9 Kb
Produced by IVT from a DNA template
Producing large amount of antigen from small dose of 
vaccine
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Kinds of mRNA vaccine 
• Encode the antigen of 
interest
• Viral replication machineryself-amplifying 
mRNA(SAM)
• Encode the antigen of 
interest
• Contain 5´& 3´UTRNon-replicatingmRNA(NMR)
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Non-replicating mRNA(NRM) 
Similar to host cell 
mRNA molecules
Encode only the 
antigen of interest
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Proof of non-amplifying mRNA
Mechanism of action of mRNA-based vaccines.2017
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Influencing factors for RNA vaccine potency
Mechanism of action of mRNA-based vaccines.2017
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mRNA delivery system
• Is not small enough to pass through cell membrane
• mRNA and cell membrane are both negatively charged
• Hydrophilic
• Highly active ubiquitous RNasa in extracellular space
Uptake rate is 1 in 10,000 molecules
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Ideal vehicle properties 
• protect RNA from ribonuclease
• Avoid entry into off-target cells
• Facilitate release into the target cell cytoplasm
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Delivery strategies
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EX vivo
• Encoded mRNA with  antigen
• Loading dendritic cells with mRNA ex vivo
• Reintroducing these DCs back in to the body
• Elicit an immune response 
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EX vivo
From the RNA world to the clinic(2016)
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100nm
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Lipid Nanoparticles (LNPs) components
• Stabilizing agent• Support Lipid 
bilayer structure
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Dendrimers
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Influencing factors for RNA vaccine potency
Mechanism of action of mRNA-based vaccines.2017
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Backbone optimization
• Phosphorothioate anti reverse cap 
analogsCap
• riboswitchesUntranslated regions
• Presenting C/G in 3th codon
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Phosphorothioate
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Result of optimization of mRNA 
5´cap
• Increase protein 
translation via 
binding to eIF4E




• Efficient protein 
production
5´UTR & 3´UTR
• Increase protein 
translati












• Affect mRNA 
secondary 
structure
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Half-life Determinants
• IVT mRNA template
• Protein product: (Crucial factor affecting pharmacokinetic and
pharmacodynamics)
from a range of a few minutes to longer than 1 week
destabilizing the mRNA might be desirable to limit the duration
of protein production. This effect can be achieved by
incorporating AU-rich elements into 3′-UTRs, thus ensuring
rapid mRNA degradation and a short duration of protein
expression
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Influencing factors for RNA vaccine potency
Mechanism of action of mRNA‐based vaccines.2017
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mRNA delivery system
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Benefit of different injection methods
Higher efficacy than
Nano particles
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Stages of innate immunity activation
• Enter cytoplasm through endocytosis
• Combine with ribosomes of host cell and translate
• Antigen protein degraded to Ag peptides by
proteasome
• Presented to cytotoxic T lymphocytes(CTLs) via
MHC1
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Stages of innate immunity activation
• Can be released out of the host cell and taken up 
by DCs
• They are degraded and presented to helper T cell 
and B cell via MHC2
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Modulation of immunogenicity
mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection 2020
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Promote T cell exhaustion 
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mRNA is inherently immunostimulatory
May provide adjuvant 
activity to drive DC 
maturation & elicit T& B 
cell immune responses
Innate immune sensing of 
mRNA is associated with 
inhibition of antigen 
expression
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Purification of IVT mRNA
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Modified nucleosides
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Adding adjuvants to optimise immunogenicity
Cationic Nano emulsion adjuvant TriMix ( CD40,CD70,TRL4)
Cure Vac AG
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• Vaccine for infectious disease( Zika, Streptococcus spp,
T.gondii )




• rare diseases and personalized medicine
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Clinical trials
The promise of mRNA vaccines: a biotech and industrial perspective,2020
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Investment
• Moderna: $2billion commercialized mRNA vaccines(2013),
Market value: $24.8 billion 
• CureVac AG: $52 million (2015)
• BioNTech: $24 million (2015) raised $325 million in July 
2020
• CEPI : $1billion to develop mRNA vaccine
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Investment
• Major pharmaceutical companies such as Novartis, Sanofi
Pasteur, AstraZeneca, Alexion and Shire
• IVT mRNA technologies are being in-licensed (for example, 
the US$240 million deal between AstraZeneca and Moderna
in 2013
• € 150.5 million Sanofi Pasteur deal with Curevac in 2014
• $100 million deal between Moderna and Alexion in 2014
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In October 2013, the 1st International mRNA Health Conference was held in the 
historic town of TÜbingen, Germany, where nucleic acid was discovered 
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